BioCentury | Mar 19, 2012
Company News

Syneron Medical, TransPharma deal

...Syneron said it will acquire "substantially all" assets of TransPharma for $3.6 million in cash. Syneron...
...to the market using its cosmetic technologies and TransPharma's patents and transdermal drug delivery systems. TransPharma's...
...wrinkle reduction, acne and cellulite. Details were not disclosed. Syneron Medical Ltd. (NASDAQ:ELOS), Yokneam, Israel TransPharma Medical Ltd....
BioCentury | Feb 28, 2011
Clinical News

ViaDor-GLP1 agonist: Phase Ib data

...Inc. (NASDAQ:AMLN, San Diego, Calif.) and Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) market Byetta. TransPharma Medical Ltd....
BioCentury | Jan 24, 2011
Clinical News

ViaDerm-Calcitonin: Phase I data

...with daily subcutaneous injections of 100 IU calcitonin. All doses of ViaDerm-Calcitonin were well tolerated. TransPharma Medical Ltd....
BioCentury | Sep 20, 2010
Clinical News

ViaDerm-GLP1 agonist: Phase Ia data

...Inc. (NASDAQ:AMLN, San Diego, Calif.) and Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) market Byetta. TransPharma Medical Ltd....
BioCentury | Sep 14, 2009
Clinical News

ViaDerm hPTH: Phase IIa data

...worldwide rights to ViaDerm-hPTH (1-34) to treat osteoporosis from TransPharma (see BioCentury, June 16, 2008). TransPharma Medical Ltd....
BioCentury | Dec 22, 2008
Clinical News

ViaDerm hPTH regulatory update

...is in Phase II testing for osteoporosis. Eli Lilly has exclusive rights to the product. TransPharma Medical Ltd....
BioCentury | Jun 16, 2008
Company News

TransPharma, Eli Lilly deal

...1-34) , a transdermal patch to treat osteoporosis. Lilly also received a non-exclusive license to TransPharma’s...
...completion of Phase II trials. Lilly will be responsible for all subsequent development and commercialization. TransPharma Medical Ltd....
BioCentury | Jun 13, 2008
Company News

Lilly, TransPharma in osteoporosis deal

...granted Eli Lilly (NYSE:LLY) exclusive, worldwide rights to develop and commercialize ViaDerm-hPTH (1-34) for osteoporosis. TransPharma...
...eligible for milestones and royalties. The peptide fragment of human parathyroid hormone delivered transdermally using TransPharma's...
...completion of Phase II testing, and Lilly will be responsible for subsequent development and commercialization. TransPharma...
BioCentury | Jul 16, 2007
Clinical News

hPTH: Phase I data

...Forteo, a peptide fragment of parathyroid hormone (PTH) approved to treat osteoporosis in post-menopausal women. TransPharma Medical Ltd....
BioCentury | Jun 18, 2007
Company News

Teva, TransPharma deal

...up to five undisclosed molecules (see BioCentury, Jan. 10, 2005). The payment was triggered by TransPharma's...
...hormone (hGH) patch completing preclinical testing. The patch, combined with a handheld electronic device, composes TransPharma's...
...Phase I/II testing to treat growth hormone deficiency. Teva Pharmaceutical Industries Ltd. (TEVA), Jerusalem, Israel TransPharma Medical Ltd....
Items per page:
1 - 10 of 18
BioCentury | Mar 19, 2012
Company News

Syneron Medical, TransPharma deal

...Syneron said it will acquire "substantially all" assets of TransPharma for $3.6 million in cash. Syneron...
...to the market using its cosmetic technologies and TransPharma's patents and transdermal drug delivery systems. TransPharma's...
...wrinkle reduction, acne and cellulite. Details were not disclosed. Syneron Medical Ltd. (NASDAQ:ELOS), Yokneam, Israel TransPharma Medical Ltd....
BioCentury | Feb 28, 2011
Clinical News

ViaDor-GLP1 agonist: Phase Ib data

...Inc. (NASDAQ:AMLN, San Diego, Calif.) and Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) market Byetta. TransPharma Medical Ltd....
BioCentury | Jan 24, 2011
Clinical News

ViaDerm-Calcitonin: Phase I data

...with daily subcutaneous injections of 100 IU calcitonin. All doses of ViaDerm-Calcitonin were well tolerated. TransPharma Medical Ltd....
BioCentury | Sep 20, 2010
Clinical News

ViaDerm-GLP1 agonist: Phase Ia data

...Inc. (NASDAQ:AMLN, San Diego, Calif.) and Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) market Byetta. TransPharma Medical Ltd....
BioCentury | Sep 14, 2009
Clinical News

ViaDerm hPTH: Phase IIa data

...worldwide rights to ViaDerm-hPTH (1-34) to treat osteoporosis from TransPharma (see BioCentury, June 16, 2008). TransPharma Medical Ltd....
BioCentury | Dec 22, 2008
Clinical News

ViaDerm hPTH regulatory update

...is in Phase II testing for osteoporosis. Eli Lilly has exclusive rights to the product. TransPharma Medical Ltd....
BioCentury | Jun 16, 2008
Company News

TransPharma, Eli Lilly deal

...1-34) , a transdermal patch to treat osteoporosis. Lilly also received a non-exclusive license to TransPharma’s...
...completion of Phase II trials. Lilly will be responsible for all subsequent development and commercialization. TransPharma Medical Ltd....
BioCentury | Jun 13, 2008
Company News

Lilly, TransPharma in osteoporosis deal

...granted Eli Lilly (NYSE:LLY) exclusive, worldwide rights to develop and commercialize ViaDerm-hPTH (1-34) for osteoporosis. TransPharma...
...eligible for milestones and royalties. The peptide fragment of human parathyroid hormone delivered transdermally using TransPharma's...
...completion of Phase II testing, and Lilly will be responsible for subsequent development and commercialization. TransPharma...
BioCentury | Jul 16, 2007
Clinical News

hPTH: Phase I data

...Forteo, a peptide fragment of parathyroid hormone (PTH) approved to treat osteoporosis in post-menopausal women. TransPharma Medical Ltd....
BioCentury | Jun 18, 2007
Company News

Teva, TransPharma deal

...up to five undisclosed molecules (see BioCentury, Jan. 10, 2005). The payment was triggered by TransPharma's...
...hormone (hGH) patch completing preclinical testing. The patch, combined with a handheld electronic device, composes TransPharma's...
...Phase I/II testing to treat growth hormone deficiency. Teva Pharmaceutical Industries Ltd. (TEVA), Jerusalem, Israel TransPharma Medical Ltd....
Items per page:
1 - 10 of 18